INV-347 for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the long-term safety of a drug called INV-347, previously tested for obesity treatment. Participants will not receive the drug again; instead, researchers will monitor how their bodies continue to process it over time. The study targets individuals who participated in a past trial and still have detectable levels of INV-347 in their blood. As a Phase 1 trial, the research focuses on understanding how the treatment functions in people, providing valuable insights into its long-term effects.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the study team or your doctor.
Is there any evidence suggesting that INV-347 is likely to be safe for humans?
Research shows that INV-347 is in the early stages of human testing, meaning complete safety information is not yet available. These early tests primarily focus on safety, with researchers closely monitoring INV-347 for any side effects. Since participants have already taken the drug, researchers are particularly interested in any long-term safety issues.
As INV-347 remains in the early testing phase, its safety is under careful study. So far, no clear reports of serious side effects have emerged. Participants should understand that the main goal is to gather as much safety information as possible.12345Why are researchers excited about this trial?
Unlike the standard treatments for obesity, which often include lifestyle changes, medications like orlistat, or even surgical options, INV-347 is unique because it is designed to assess long-term safety after initial human exposure. Researchers are excited about INV-347 because it may offer a novel approach by maintaining measurable plasma exposure over time, which could potentially lead to sustained effects in managing obesity. This ongoing exposure might help in understanding the long-term impact and safety of the treatment, which is a crucial consideration for chronic conditions like obesity.
What evidence suggests that INV-347 might be an effective treatment for obesity?
Research has shown that INV-347 led to significant weight loss in earlier studies, with noticeable results in just 28 days. This drug blocks a specific receptor in the brain, helping to reduce appetite and support weight loss. Some participants reported mild to moderate side effects, such as anxiety. Although Novo Nordisk decided not to continue developing INV-347, the initial results for weight loss were promising. Those interested in this treatment should consider the potential benefits and possible side effects.26789
Who Is on the Research Team?
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
This trial is for individuals who were previously given the drug INV-347 in an earlier study (INV-CL-108) and are being monitored for safety. The focus is on those with obesity, but no new participants will be dosed.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Safety Follow-up
Participants are monitored for safety and blood levels of INV-347 without receiving any study drug
End-of-study visit
Final assessment of participants' safety and any adverse events
What Are the Treatments Tested in This Trial?
Interventions
- INV-347
Trial Overview
The trial monitors long-term safety and blood levels of INV-347 in past participants. It's a follow-up study without additional drug administration, lasting approximately 2 years to track any delayed effects.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen
Citations
1.
tipranks.com
tipranks.com/news/company-announcements/novo-nordisks-inv-347-safety-study-key-insights-for-investorsNovo Nordisk's INV-347 Safety Study: Key Insights for ...
The primary objective is to assess the long-term safety and blood levels of the drug INV-347 in participants who were previously dosed in the ...
2.
novonordisk.com
novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2025/Q1-2025-investor-presentation.pdfInvestor presentation First three months of 2025
NN9441 – INV-347. NN9542 – OW GIP/GLP-1 co-agonist. NN6535 – Oral ... outcomes data. Develop next-generation treatments. Page 60. 60. Novo ...
3.
synapse.patsnap.com
synapse.patsnap.com/blog/novo-nordisk-completes-phase-2a-clinical-study-of-new-weight-loss-productNovo Nordisk Completes Phase 2a Clinical Study of New ...
While the drug demonstrated significant weight loss effects, the mild to moderate neuropsychiatric side effects, specifically anxiety, ...
News & Events
-Study results demonstrated favorable safety, tolerability, and PK profile -Clinically significant weight loss was observed in only 28 days -Positive trends in ...
5.
fiercebiotech.com
fiercebiotech.com/biotech/novo-nordisk-drops-2-obesity-drugs-part-major-pipeline-clearoutNovo Nordisk drops 2 obesity drugs during pipeline clearout
The drugmaker also revealed that it has given up on INV-347, a next-generation CB1 receptor blocker acquired as part of the buyout of Inversago ...
6.
theglobeandmail.com
theglobeandmail.com/investing/markets/stocks/NVO/pressreleases/35740621/novo-nordisks-inv-347-safety-study-key-insights-for-investors/Novo Nordisk's INV-347 Safety Study: Key Insights for ...
This research is significant as it aims to ensure the safety of INV-347, which is being developed for obesity treatment. Intervention/Treatment: ...
Find a clinical trial
... Long-term Effects of Semaglutide in ... Obesity A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity.
8.
novonordisk.com
novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/ada/novo-nordisk-r-and-d-investor-event.pdfNovo Nordisk R&D Investor Event
INV-347. Phase 1 ongoing. Triple (tri-agonist). Phase 1 ... • 33 million patient years of exposure of sema3 supporting long-term safety.
Clinical trial updates on INV-202 and INV-347
In January 2024, Novo Nordisk initiated a phase 1 trial with a next-generation oral small molecule CB1 receptor blocker INV-347.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.